<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091117</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2009-00059</org_study_id>
    <secondary_id>NCI-2009-00059</secondary_id>
    <secondary_id>CDR0000383782</secondary_id>
    <secondary_id>C-2802</secondary_id>
    <secondary_id>C-2802</secondary_id>
    <secondary_id>6432</secondary_id>
    <secondary_id>U01CA062487</secondary_id>
    <secondary_id>U01CA062505</secondary_id>
    <secondary_id>U01CA069853</secondary_id>
    <secondary_id>U01CA062491</secondary_id>
    <secondary_id>U01CA070095</secondary_id>
    <nct_id>NCT00091117</nct_id>
  </id_info>
  <brief_title>Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction</brief_title>
  <official_title>A Phase I Pharmacokinetic Study of PS-341 in Patients With Advanced Malignancies and Varying Degrees of Liver Dysfunction for the CTEPSponsored Organ Dysfunction Working Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their&#xD;
      growth. This phase I trial is studying the side effects and best dose of bortezomib in&#xD;
      treating patients with advanced cancer and liver dysfunction.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. Determine the maximum tolerated dose of bortezomib in patients with advanced malignancies&#xD;
      and varying degrees of liver dysfunction.&#xD;
&#xD;
      II. Determine the safety and tolerability of this drug in these patients. III. Determine the&#xD;
      pharmacokinetics and pharmacodynamics of this drug in these patients with mild, moderate, or&#xD;
      severe liver insufficiency.&#xD;
&#xD;
      IV. Examine the dietary influences on bortezomib disposition and efficacy. V. Examine the&#xD;
      influences of proteasome inhibition on CYP 450 activity.&#xD;
&#xD;
      OUTLINE: This is a multicenter, dose-escalation study. Patients are stratified according to&#xD;
      hepatic function (normal vs mild dysfunction vs moderate dysfunction vs severe dysfunction).&#xD;
&#xD;
      Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11.&#xD;
&#xD;
      Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.&#xD;
      Cohorts of 3-6 patients per stratum receive escalating doses of bortezomib until the maximum&#xD;
      tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2&#xD;
      of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
      [Note: Patients with normal hepatic function do not receive escalating doses of bortezomib.]&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <primary_completion_date type="Actual">March 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>MTD</measure>
    <time_frame>21 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Hepatic Complications</condition>
  <condition>Malignant Neoplasm</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bortezomib</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>LDP 341</other_name>
    <other_name>MLN341</other_name>
    <other_name>VELCADE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed malignancy for which no known standard therapy that is&#xD;
             potentially curative or definitely capable of extending life expectancy exists&#xD;
&#xD;
          -  Tumor types may include any of the following: solid tumors:&#xD;
&#xD;
               -  Non-Hodgkin's lymphoma&#xD;
&#xD;
               -  Hepatocellular carcinoma, as evidenced by liver mass, elevated alpha-fetoprotein&#xD;
                  level (&gt;= 500 ng/mL), and positive serology for hepatitis&#xD;
&#xD;
          -  Pathological confirmation is not required&#xD;
&#xD;
          -  Confirmatory evidence for a prior Hepatitis B infection (HBsAg, HBcAb and/or HBsAb)&#xD;
             required&#xD;
&#xD;
          -  No symptomatic CNS metastases&#xD;
&#xD;
          -  Brain metastasis allowed if the following criteria are met:&#xD;
&#xD;
               -  Received prior definitive treatment (radiation and/or surgery&#xD;
&#xD;
               -  Stable disease for &gt;= 4 weeks&#xD;
&#xD;
               -  Not currently on enzyme-inducing anticonvulsants and steroids&#xD;
&#xD;
          -  Life expectancy of at least 12 weeks&#xD;
&#xD;
          -  Absolute neutrophil count &gt;= 1,000/mm^3&#xD;
&#xD;
          -  Platelet count &gt;= 100,000/mm^3&#xD;
&#xD;
          -  Biliary obstruction for which a shunt has been placed allowed provided the shunt has&#xD;
             been in place for &gt;= 10 days AND liver function is stable, defined as 2 measurements&#xD;
             taken &gt;= 2 days apart that qualify the patient for the same hepatic dysfunction&#xD;
             stratum&#xD;
&#xD;
          -  No biliary sepsis&#xD;
&#xD;
          -  Creatinine =&lt; 1.5 mg/dL&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No New York Heart Association class III or IV heart disease&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No preexisting neuropathy &gt;= grade 2&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No other concurrent uncontrolled illness that would preclude study participation&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  More than 4 weeks since prior immunotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior biologic therapy&#xD;
&#xD;
          -  No concurrent prophylactic colony-stimulating factors&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
          -  No concurrent thalidomide&#xD;
&#xD;
          -  Concurrent epoetin alfa or darbepoetin alfa for management of cancer-associated anemia&#xD;
             allowed&#xD;
&#xD;
          -  Recovered from prior chemotherapy (not including liver function)&#xD;
&#xD;
          -  More than 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)&#xD;
&#xD;
          -  No concurrent chemotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to &gt; 50% of the bone marrow&#xD;
&#xD;
          -  No concurrent radiotherapy&#xD;
&#xD;
          -  More than 3 weeks since prior surgery&#xD;
&#xD;
          -  No prior bortezomib&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  Concurrent cytochrome P450 interacting agents are allowed provided they are used with&#xD;
             caution&#xD;
&#xD;
          -  Concurrent bisphosphonate therapy allowed (e.g., pamidronate or zoledronate), except&#xD;
             during course 1 of bortezomib administration&#xD;
&#xD;
          -  ECOG 0-2&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 30 days after study&#xD;
             participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia LoRusso</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>City of Hope Medical Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-8936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
  </removed_countries>
  <verification_date>December 2013</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 7, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2004</study_first_posted>
  <last_update_submitted>December 13, 2013</last_update_submitted>
  <last_update_submitted_qc>December 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Liver Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bortezomib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

